Results 51 to 60 of about 10,024 (235)

Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial. [PDF]

, 2023
The antiviral drug molnupiravir was licensed for treating at-risk patients with COVID-19 on the basis of data from unvaccinated adults. We aimed to evaluate the safety and virological efficacy of molnupiravir in vaccinated and unvaccinated individuals ...
Ahmad, Shazaad, Buadi, Amanda, Bullock, Katie, Byrne, Rachel, Cameron, David, Chiong, Justin, Cubas Atienzar, Ana, Darbyshire, Janet, Donovan-Banfield, I'ah, Downs, Nichola, Edwards, Christopher J., Edwards, Thomas, Ewings, Sean, FitzGerald, Richard, Fletcher, Tom, Freedman, Andrew, Greenhalf, William, Griffiths, Gareth, Hadjiyiannakis, Dennis, Hale, Colin, Hayden, Fred, Hiscox, Julian A., Holman, Wayne, Jacobs, Michael, Jaki, Thomas, Jones, Jayne, Julious, Stevan, Khoo, Saye H., Knight, Richard, Knox, Emma, Lalloo, David, Lavelle-Langham, Lara, Lorch, Ulrika, Lucas, Amy, Lyon, Rebecca, Middleton, Calley, Mozgunov, Pavel, Northey, Josh, Painter, Wendy, Paton, Nicholas, Periselneris, Jimstan, Reynolds, Helen, Rowland, Tim, Saunders, Geoffrey, Shaw, Victoria, Song, Anna, Tetlow, Michelle, Walker, Lauren, Williams, Chris, Woods, Christie   +49 more
core   +2 more sources

Could chlorophyllins improve the safety profile of beta-d-N4-hydroxycytidine versus N-hydroxycytidine, the active ingredient of the SARS-CoV-2 antiviral molnupiravir?

Therapeutic Advances in Drug Safety, 2022
Plain Language Summary Could natural plant pigment (chlorophyll) derivatives (chlorophyllins) improve the safety of the antiviral Molnupiravir, used to treat COVID-19 disease?
Nicole F. Clark, Andrew W. Taylor-Robinson, Kirsten Heimann   +2 more
doaj   +1 more source

An exploratory binding study of molnupiravir efficacy against emerging Omicron SARS-CoV-2 variants. [PDF]

Sci Rep
SARS-CoV-2 (severe acute respiratory syndrome causing coronavirus 2) caused an epidemic that swept the globe and resulted in large number of casualties.
Ahmad F, Basharat Z, Janjua A, Najmi MH, Almajhdi FN, Hussain T, Ozsahin DU, Waheed Y.   +7 more
europepmc   +2 more sources

Effectiveness of molnupiravir vs nirmatrelvir-ritonavir in non-hospitalised and hospitalised patients with COVID-19: a target trial emulation studyResearch in context

EClinicalMedicine, 2023
Summary: Background: Molnupiravir and nirmatrelvir-ritonavir have emerged as promising options for COVID-19 treatment, but direct comparisons of their effectiveness have been limited.
Eric Yuk Fai Wan, Vincent Ka Chun Yan, Zoey Cho Ting Wong, Celine Sze Ling Chui, Francisco Tsz Tsun Lai, Xue Li, Carlos King Ho Wong, Ivan Fan Ngai Hung, Chak Sing Lau, Ian Chi Kei Wong, Esther Wai Yin Chan   +10 more
doaj   +1 more source

Safety Profile of Molnupiravir in the Treatment of COVID-19: A Descriptive Study Based on FAERS Data [PDF]

, 2023
Concerns have been raised about the actual benefit and safety of molnupiravir, a new antiviral treatment for coronavirus disease 2019 (COVID-19). In order to provide additional evidence to support its use, we aimed to evaluate the real safety profile ...
Montanaro N., Motola D., Santi Laurini G.   +2 more
core   +1 more source

How Can Pharmacology Help Us Overcome the Challenges of Drug Repositioning as Antivirals to Treat Emerging Pathogens? The Example of Covid-19. [PDF]

Clin Transl Sci
Pharmacological pitfalls and challenges in drug repurposing for emerging pathogens: lessons from COVID‐19. ABSTRACT The Covid‐19 pandemic highlighted the urgent need for effective therapies against emerging pathogens. Drug repurposing, defined as the use of existing medications for new therapeutic purposes, was extensively pursued for SARS‐CoV‐2 but ...
Ben Ghezala I, Peiffer-Smadja N, Solas C, Nougairède A, Touret F, Bardou M.   +5 more
europepmc   +2 more sources

Earth-friendly-assessed silver-nanoparticles spectrophotometric method for rapid and sensitive analysis of Molnupiravir, an FDA-approved candidate for COVID-19: application on pharmaceutical formulation and dissolution test

BMC Chemistry, 2023
Molnupiravir is the first oral direct-acting antiviral prodrug recently approved for the COVID-19 pandemic. Here and for the first time, we present a novel, sensitive, robust, and simple silver-nanoparticles spectrophotometric technique for molnupiravir ...
Ahmed R. Mohamed, Ebrahim Abolmagd, Israa M. Nour, Mohamed Badrawy, Mohamed A. Hasan   +4 more
doaj   +1 more source

Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system

Frontiers in Pharmacology, 2023
Molnupiravir, an urgently approved drug during the Coronavirus Disease 2019 (COVID-19) pandemic, serves as the basis for our study, which relies on the Food and Drug Administration Adverse Event Reporting System (FAERS).
Yankun Liang, Yankun Liang, Lin Ma, Yuting Wang, Jingping Zheng, Ling Su, Jun Lyu, Jun Lyu   +7 more
doaj   +1 more source

Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir as treatments for COVID-19 in patients at high risk [PDF]

, 2023
Background Using a retrospective cohort study design, we aimed to evaluate the effectiveness of molnupiravir and nirmatrelvir/ritonavir in patients with SARS-CoV-2 who were highly vulnerable. Methods The impact of each drug was determined via comparisons
Antoniadou, Anastasia, Filippou, Dimitrios, Gaga, Mina, Gerolymatos, Gerasimos, Gkolfinopoulou, Kassiani, Gkova, Maria, Kostaki, Evangelia-Georgia, Kotanidou, Anastasia, Loukides, Stylianos, Mellou, Kassiani, Mossialos, Elias, Paraskevis, Dimitrios, Psalida, Naya, Saroglou, Georgios, Skoutelis, Athanasios, Thiraios, Eleftherios, Tsiodras, Sotirios, Zaoutis, Theoklis, Zografopoulos, Dimitrios   +18 more
core   +1 more source

Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life [PDF]

, 2023
Background. Several drugs which are easy to administer in outpatient settings have been authorized and endorsed for high-risk COVID-19 patients with mild–moderate disease to prevent hospital admission and death, complementing COVID-19 vaccines.
Francesca Larese Filon, Luca Cegolon, Omar Simonetti, Riccardo Pol, Roberto Luzzati   +4 more
core   +1 more source